Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | PER2 | O15055 | 10/20 | 0.42 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681916 | 0.89 | CHRM2 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11288962 | 0.83 | — | — | |
| SCHEMBL4330615 | 0.82 | CHRM2 (0.49) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13293935 | 0.81 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10017998 | 0.81 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5331770 | 0.80 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7621988 | 0.80 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1869119 | 0.78 | MEN1 (0.48) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19218077 | 0.78 | PDK2 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20628520 | 0.77 | CHRM2 (0.49) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115996796-B | Trimetallic catalysts made of nickel, molybdenum and tungsten and their use in hydrotreating and/or hydrocracking processes | IFP 新能源公司 | 2024-11-19 | — | — | CN | disclosed |
| EP-2802634-B1 | BINDER SOLUTIONS | CHEMOURS CO FC LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2802629-B1 | AQUEOUS BINDER SOLUTIONS | CHEMOURS CO FC LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9580609-B2 | Aqueous binder solutions | THE CHEMOURS COMPANY FC, LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9518189-B2 | Binder solutions | THE CHEMOURS COMPANY FC, LLC (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160347958-A1 | AQUEOUS BINDER SOLUTIONS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | disclosed |
| US-20140378584-A1 | BINDER SOLUTIONS | THE CHEMOURS COMPANY FC, LLC | 2014-12-25 | — | — | US | disclosed |
| EP-2802634-A1 | BINDER SOLUTIONS | E. I. Du Pont de Nemours and Company (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2802629-A1 | AQUEOUS BINDER SOLUTIONS | E. I. Du Pont de Nemours and Company (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013106421-A1 | BINDER SOLUTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2004084633-A1 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID WITH NITRO COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085348-A2 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085048-A2 | PRODUCTION OF 5-METHYL-N-(METHYL ARYL)-2-PYRROLIDONE, 5-METHYL-N-(METHYL CYCLOALKYL)-2-PYRROLIDONE AND 5- METHYL-N-ALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEUVLINIC ACID ESTERS WITH CYANO COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085347-A2 | PRODUCTION OF N-ARYL-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYL NITRO COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084887-A1 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5- METHYL-N-CYCLOALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID WITH ARYL AMINES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085047-A2 | PRODUCTION OF N-(METHYL-ARYL)-2-LACTAM, N-(METHYLCYCLOAKLYL)-2-LACTAM AND N-ALKYL-2-LACTAM | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084888-A1 | PRODUCTION OF 5-METHYL-N-(METHYL ARYL)-2-PYRROLIDONE, 5-METHYL-N-(METHYL CYCLOALKYL)-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192933-A1 | Production of 5-methyl-1-hydrocarbyl-2-pyrrolidone by reductive amination of levulinic acid | E.I. DU PONT DE NEMOURS AND COMPANY | 2004-09-30 | — | — | US | disclosed |
| US-20040192938-A1 | Production of 5-mehyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-09-30 | — | — | US | disclosed |
| US-6743819-B1 | METAL CATALYST | E. I. DU PONTE DE NEMOURS AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192933-A1 | Production of 5-methyl-1-hydrocarbyl-2-pyrrolidone by reductive amination of levulinic acid | ALDH18A1, PRMT5, PYCR1 | CHRM2 1334/4885CHRM4 2126/4885CHRM5 462/4885 |
| US-20040192938-A1 | Production of 5-mehyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | PAH, ALDH18A1, PNPO | CHRM2 1879/4885CHRM4 1976/4885CHRM5 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.